Alfabetex® is more effective than monotherapies

Alfabetex® (Valsartan + HCTZ) ensures more Systolic and Diastolic BP control and high Patient Response.

Efficacy of Alfabetex® vs Amlodipine + HCTZ

Alfabetex® (Valsartan+HCTZ) is superior to (Amlodipine + HCTZ) for achieving BP control, and avoiding excessive treatment adjustments and maintaining tolerability.
**Alfabetex® in Diabetic Hypertensive Patients**

Valsartan reduces the rate of urinary albumin excretion independently of blood Pressure figures, in Patients with Diabetes Mellitus.

**Alfabetex® Efficacy in hypertensive patients with CAD**

JIKEI HEART Study

Valsartan significantly reduced the incidence of Myocardial infarction, angina pectoris and congestive heart failure particularly in the high risk patients with CAD.

*CAD = Coronary Artery Disease.
**LVMI = Left ventricular myocardial infarction.
Alfabetex® significantly reduces SBP and DBP in mild, moderate and severe hypertensive patients.
Alfabetex® has 24 hours efficacy with once daily dosing.
Alfabetex® has significant renoprotective effect in diabetic-hypertensive patients.
Alfabetex® has high tolerability profile.
Alfabetex® has proven efficacy in hypertensive patients with CAD.
Alfabetex® has significant regression in LVH* in hypertensive patients.
Alfabetex® can be taken with or without food.

**Dosage:**

The recommended dose of **Alfabetex®** is 80/12.5 mg or 160/25 mg, 1 tablet per day depending on patient’s response.

LVH* = left ventricular hypertrophy

References:

Alpha Group

Cairo: Elsoudia co. Buildings from Elnozha st., Heliopolis building no. 10 2nd floor
Tel & Fax : 02/ 24197364
Alex: Smouha / Elsaraya Buildings., Orchid building, flat no. 1001, 10th floor
Tel : 034294864 – 034294866 Mob : 01211115515
Email : alphagroupcompany@gmail.com
www.alphagroupecgypt.com